Skip to main content
Evidence Snapshot

Ileal sodium/bile acid cotransporter

CHEMBL2778 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:49Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2778
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ileal sodium/bile acid cotransporter as ChEMBL target CHEMBL2778, mapped to UniProt Q12908. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ileal sodium/bile acid cotransporter
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2778
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q12908
Ileal sodium/bile acid cotransporter
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Ileal sodium/bile acid cotransporter matters

As of 2026-09-13

Ileal sodium/bile acid cotransporter is reviewed as Ileal sodium/bile acid cotransporter (UniProt Q12908); Ileal sodium/bile acid cotransporter shows approved-linked disease relevance led by intrahepatic cholestasis. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 344 compounds, and 46 assays, with lead potency reaching pChEMBL 9.6.

Disease context
intrahepatic cholestasis

Ileal sodium/bile acid cotransporter shows approved-linked disease relevance led by intrahepatic cholestasis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include LINERIXIBAT, ODEVIXIBAT, ODEVIXIBAT SESQUIHYDRATE.

Start review with intrahepatic cholestasis because it currently carries approved-linked support. Linked drugs include LINERIXIBAT, ODEVIXIBAT, ODEVIXIBAT SESQUIHYDRATE, VOLIXIBAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 344 compounds, and 46 assays for this target. The dominant activity type is IC50. CHEMBL363392 is the current potency anchor at pChEMBL 9.6.

Use CHEMBL363392 as the tractability anchor when discussing potency (pChEMBL 9.6).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 9.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Ileal sodium/bile acid cotransporter matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q12908, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why intrahepatic cholestasis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

344
Total Compounds
46
Total Assays
7
Approved Drugs
IC50: 289.0, KI: 51.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL363392
 9.6 IC50 Approved
No preferred name
CHEMBL370103
 9.5 IC50 —
No preferred name
CHEMBL364676
 9.3 IC50 —
No preferred name
CHEMBL194685
 9.1 IC50 —
No preferred name
CHEMBL555246
 9.1 IC50 —

Approved Drugs

Structure Compound First Approval
MARALIXIBAT
CHEMBL363392
 2021
MARALIXIBAT CHLORIDE
CHEMBL17879
 2021
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:49Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2778